Page 3 of 6
Overall, 102 patients received at least one dose of mepolizumab in this study. The
study included 47 (46%) males and 55 (54%) females. The average age was 46 years.
The youngest patient was 13 years old and the oldest patient was 81 years old.
For more detailed information about the patients included in this study, see the
scientific results summaries (links to those summaries are provided at the end of this
document).
Where was this study done?
Study sites were in 13 countries.
Number of patients who received at least one dose of
mepolizumab
Argentina 6
Belgium 10
Brazil 3
France 17
Germany 13
Italy 5
Mexico 5
Poland 10
Romania 2
Russian Federation 7
Spain 3
United Kingdom 6
United States 15
0 5 10 15 20
Number of patients
What were the main results of the study?
Safety was measured by:
• Recording the number of patients who had adverse events.
• Checking the patients’ blood samples for the presence of anti-mepolizumab
antibodies.